MDS with PNH clone (3)

About this case study

MDS with PNH clone (3)

Flow cytometry
Details of flow cytometry instrument


Cell populations evaluated for PNH clones:

Granulocytes, monocytes, RBCs

Treatments received (if applicable):

Myelodysplastic syndrome (RA – WHO)

External control:


Antibodies/reagents and gating strategies used:

FLAER-Alexa 488, CD14 (61D3)-PE, CD15 (H198)-APC, CD24 (SN3)-PE, CD64 (10.1)-PE, CD45 (2D1)-PerCP-Cy5.5, CD59 (MEM43)-PE, CD235a (KC16)-FITC Practical Guidelines 2012

Clone sizes in all populations tested:

Granulocytes: 44.6% (Type II + III)
Monocytes: 60.6% (Type II + III)
RBCs: 17.9% (Type III), 0.7% (Type II)

LDH level:19.8 µkat/L (2.2–3.6)
RBC count:3.54 x 1012/L (4.70–6.10)
WBC and neutrophil counts:5.3 x 109/L (4.00–10.80)
Platelet count:120.00 x 109/L (150.00–400.00)
FLAER, fluorescent aerolysin; LDH, lactate dehydrogenase; MDS, myelodysplastic syndrome; RA, refractory anaemia; RBC, red blood cell; WBC, white blood cell; WHO, World Health Organization

Netflow - MDS with PNH clone (3)

FC data

Netflow - MDS with PNH clone (3)

Dot plots

aAll case study files are provided with permission from the Steering Committee and other registered users of the website and are for personal use only, not for distribution